Eczema Skin Health Tracker

Flare coverage percentage — the number dermatologists track

The Flare Coverage field accepts 0–100% of body surface area. The BSA-based estimate is a standard component of clinical eczema scoring systems like EASI and SCORAD. Mild eczema is typically under 10% BSA; moderate is 10–30%; severe is above 30%. You do not need to measure precisely — a rough visual estimate (hands covering about 1% BSA; the back about 18%) gives a consistent enough number for trend tracking.

Logging coverage alongside itch severity matters because the two often diverge. Someone with 20% coverage but very controlled itch is in a different functional state than someone with 8% coverage that is intensely pruritic. The combination of both scores gives your dermatologist a multi-dimensional picture of your disease state rather than just an area measurement.

Moisturizer routine and the skin barrier connection

The Moisturizer Routine field ranges from Skipped today through Once daily, Twice daily, Three times daily, and Full routine (4+x). This input carries significant weight in the Eczema Control Score because emollient therapy is the foundation of eczema management — not a nice-to-have addition. A compromised skin barrier is central to eczema pathophysiology, and consistent moisturizer use reduces transepidermal water loss and helps maintain barrier integrity.

The tracker correlates your moisturizer consistency with your itch and coverage scores over time. Most people with eczema notice that weeks with consistent twice-daily or more application correspond to lower itch and coverage numbers. When that correlation is visible in your log, it is motivating in a way that general advice is not. It also gives you something concrete to discuss with a dermatologist: 'When I moisturize three times daily, my itch drops from 6 to 3 on average.'

Itch severity and sleep disruption — the feedback loop

Sleep disruption is one of the most significant quality-of-life impacts of eczema, and the tracker captures it directly through both Sleep Hours and Sleep Quality — with a customized scale for eczema specifically: Poor means 'woke up scratching,' and Disrupted means 'some sleep loss.' This is more precise than a generic sleep quality rating because it names the eczema-specific mechanism.

The feedback loop is real: night-time itching disrupts sleep, poor sleep reduces the skin's repair capacity and elevates inflammatory markers, which worsens itch the following night. By logging both itch severity and sleep quality each day, you build a documented record of this cycle — useful both for quantifying the impact with your care team and for identifying whether specific interventions (evening wet wrap therapy, bedtime topical, antihistamine for sleep) are breaking the cycle.

Treatment tiers — from OTC to biologic therapy

The Current Treatment field has four options: No treatment, OTC creams/lotions, Prescription treatment, and Biologic therapy. This range reflects the actual treatment ladder for eczema: low-potency emollients, OTC hydrocortisone and barrier creams at the base; prescription topical corticosteroids and calcineurin inhibitors at the next level; and biologics like dupilumab for moderate-to-severe atopic dermatitis at the top.

The treatment tier provides context for interpreting your score. An Eczema Control Score of 55 while on biologic therapy suggests the biologic may not be achieving adequate control and warrants a conversation with your dermatologist. The same score while using OTC creams only may indicate that prescription treatment is appropriate. The score's usefulness depends on honest treatment logging — select the tier that reflects what you are actually using.

Using the tracker to identify personal triggers

Common eczema triggers include certain fabrics, detergents, fragrances, pet dander, temperature and humidity changes, stress, sweat, and specific foods in some individuals. The tracker does not have a dedicated trigger field but the notes functionality and the daily pattern view together let you annotate days when you know you encountered a potential trigger. Over several weeks, the correlation between logged triggers and next-day itch spikes often reveals a personal trigger pattern.

A person who notices that itch severity consistently runs 2–3 points higher in the days following wool fabric exposure has confirmed information, not just a suspicion. Similarly, someone who sees reliable itch reduction during low-stress, high-sleep weeks has identified sleep management as a meaningful lever in their eczema control. Track it daily — your itch and trigger history stays private, free to start, no card ever required. Log 30 days of severity + triggers + treatment to bring real-world POEM-style data to your dermatologist → Log 30 days of severity + triggers + treatment to bring real-world POEM-style data to your dermatologist →

Important: this is a self-tracking tool, not medical advice

This tracker is a self-monitoring tool, not a diagnostic device. The information you enter and the scores it produces are for personal awareness and for sharing with your clinician — they are not a substitute for professional medical evaluation, diagnosis, or treatment. Do not change medication, dose, or treatment plan based on this tool. If you experience symptoms that concern you, contact your clinician; for emergencies in the US, call 911 or your local emergency number. Mental health crisis support in the US is available 24/7 by calling or texting 988.

Eczema Skin Health Tracker vs. the alternatives

How to use it

1. Rate Itch Severity (0–10) at the same time each day — evening is often most informative since itch typically worsens at night.
2. Enter Flare Coverage as a rough percentage of body surface area currently affected, then rate Skin Dryness (0–10).
3. Select Moisturizer Routine frequency from the dropdown — be honest, since this field significantly influences the Control Score.
4. Choose your Current Treatment tier and log Sleep Hours and Sleep Quality from last night.
5. Check the Eczema Control Score and the skin status summary, then note any trigger exposures or relevant activities in your log.

Who it's for

• Person with moderate atopic dermatitis starting dupilumab — Logs itch severity and flare coverage weekly before and after starting biologic therapy, documenting the treatment response timeline to share with their dermatologist at the eight-week follow-up.
• Adult managing eczema primarily through moisturizer and avoidance — Tracks moisturizer consistency alongside itch scores for six weeks, confirming that twice-daily application correlates with an average itch reduction of 2–3 points on their personal scale.
• Parent tracking a child's eczema flares — Logs the child's flare coverage and sleep quality daily to document the severity of sleep disruption for their pediatric dermatologist and make the case for stepping up treatment.
• Person investigating a potential fabric or detergent trigger — Notes in the daily log when they wear a specific fabric or use a new detergent, looking for correlation with next-day itch spikes to confirm or rule out the trigger.

Key terms

Atopic dermatitis

The most common form of eczema, characterized by dry, itchy, inflamed skin. Associated with a genetic predisposition to skin barrier dysfunction and immune hypersensitivity.

TEWL (transepidermal water loss)

The passage of water through the skin into the environment. Elevated in eczema due to impaired skin barrier function; consistent moisturizer use helps reduce TEWL.

Emollient

A moisturizer that reduces water loss from the skin by forming a protective layer. Central to eczema management; thicker formulations (ointments) are generally more effective than lighter lotions.

BSA (body surface area)

A way to express the extent of skin involvement as a percentage of the total skin surface. Used in clinical eczema scoring systems like EASI and SCORAD.

Sources & further reading

• National Eczema Association — Eczema overview
• American Academy of Dermatology — Eczema
• NIAMS — Atopic Dermatitis
• International Eczema Council
• PubMed — Patient-reported outcomes in atopic dermatitis